September 11, 2020
Chugai Pharmaceutical and Takeda Pharmaceutical will jointly develop in Japan the combination therapy of the anti PD-L1 antibody Tecentriq (atezolizumab) and the tyrosine kinase inhibitor Cabometyx (cabozantinib) in multiple cancer types by joining in on global PIII studies, the companies...read more